ArticleJournal of medicinal chemistry2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Unique fluoroalkyl substituents: is there life after CFChemical science · 2026Review
- Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient Impact.Journal of medicinal chemistry · 2026Review
- Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Initiation of Long-Acting Antiretroviral Combinations Achieve Sustained Virologic Remission in Early-Life SIV Infection.Research square · 2026Article
- Structural, biophysical, and virological mechanistic characterization of HIV-1 capsid-targeting antivirals.bioRxiv : the preprint server for biology · 2025Article
- Design, synthesis and profiling of highly potent antivirals targeting emerging drug-resistant HIV-1 variants.bioRxiv : the preprint server for biology · 2025Article
- Use of the Split Luciferase Complementation Assay to Identify Novel Small Molecules That Disrupt Essential Protein-Protein Interactions of Viruses.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Eda CanalesMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Winston TseMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Scott D SchroederMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.ORCID 0009-0009-0472-6128
Chien-Hung ChouMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Qi LiuMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Jennifer ZhangMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Scott E LazerwithMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Philip MorganelliMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Roland D SaitoMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Gediminas BrizgysMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Jiayao LiMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Qiaoyin WuMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Michael GraupeMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Randall L HalcombMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Manoj DesaiMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Carina CannizzaroStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Eric HuStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Jason K PerryStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.ORCID 0000-0001-5492-0652
Armando G VillaseñorStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
John R SomozaStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Ryan D FerraoStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
S SwaminathanStructural Biology and Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Jim ZhengDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Bing LuDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Judy MwangiDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Kelly WangDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Raju SubramanianDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Bill J SmithDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Gerry RhodesDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
William RoweFormulation and Process Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Dorothea SauerFormulation and Process Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Latesh LadResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Giuseppe A PapaliaResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Sheila ClancyResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
George J StepanResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Helen YuResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Roman SakowiczResearch Discovery Sciences and Technologies, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Bing ShiProcess Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Gavin CarrProcess Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Rujuta A BamDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Luong K TsaiDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Eric SingerDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Derek HansenDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Andrew MulatoDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Stephen R YantDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Tomas CihlarDiscovery Virology, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
John O LinkMedicinal Chemistry, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California 94404, United States.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HIV capsid is essential to the virus lifecycle, making it a promising target for therapeutic intervention. In 2006, a screening campaign was initiated to identify small molecules capable of disrupting the protein-protein interactions required for self-assembly of the 1500 capsid monomers that form the 37 MDa fullerene cone-shaped capsid. Numerous compound design cycles over many years were undertaken to discover the complex structural elements that together afford the multistage HIV capsid inhibitor lenacapavir. Lenacapavir is the most potent (HIV-1 EC
Indexed as
Anti-HIV AgentsCapsidHIV-1HIV InfectionsPre-Exposure ProphylaxisAcetamidesDrug DiscoveryFemaleHumansIndazolesStructure-Activity RelationshipAcetamidesAnti-HIV AgentsIndazoleslenacapavir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.